Fortrea Holdings Inc. (NASDAQ:FTRE), a healthcare technology and distribution company, faces divergent analyst views on its turnaround.
Recent upgrades highlight improving fundamentals, while concerns about profitability and financial transparency linger.
The company has new leadership under Anshul Thakral, seen as bringing stability and better execution.
Fortrea's financial trajectory shows improvement. Revenue is projected to grow from $2,734 million (FY2025) to $2,884 million (FY2027).
EBITDA is expected to rise from $180 million (FY2025) to $268 million (FY2027). EPS estimates climb from $0.60 to $1.72 over the same period.
Organic revenue growth is projected at ~2% in 2026, accelerating to 4% by 2028.
Margin expansion is central to the turnaround story, with operating margin expected to expand by ~160 basis points in 2026.
The biopharma industry environment is improving, with clearer drug pricing policies reducing uncertainty.
Fortrea stock has returned 226% over the past year, trading at $13.22 with a market cap of ~$1.25 billion.
Debt burden is significant: gross debt to EBITDA stands at ~6x. Management aims to reduce it to ~4x by end of 2026.
Analysts note challenges in analyzing Fortrea's finances due to pass-through expenses, which obscure true operational performance.
The disconnect between strong bookings and margin deterioration raises questions about business model sustainability.
The bullish case relies on improved biopharma spending, but cycles have historically been volatile.
New leadership offers fresh perspectives. Analysts project 160 bps operating margin expansion in 2026.
This analysis is based on information from November 2025 through January 2026.
